Perioperative blood transfusion and outcome

Current Opinion in Anaesthesiology

Volumn 19, Issue 2, 2006, Pages 198-206

  Strumper Groves, Danja ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Allogeneic blood transfusion; Immunomodulation; White blood cell reduction

Indexed keywords

HEMOGLOBIN;

ACUTE LUNG INJURY; ANEMIA; BLOOD AUTOTRANSFUSION; BLOOD STORAGE; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CANCER RECURRENCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; HUMAN; IMMUNOMODULATION; INFECTIOUS COMPLICATION; INTENSIVE CARE UNIT; LENGTH OF STAY; LEUKAPHERESIS; LEUKOCYTE COUNT; LUNG FUNCTION; MORTALITY; OUTCOMES RESEARCH; PERIOPERATIVE PERIOD; PHLEBOTOMY; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PURPURA; REVIEW; RISK; SURGICAL PATIENT; TREATMENT OUTCOME;

ANEMIA; BLOOD PRESERVATION; BLOOD TRANSFUSION; BLOOD TRANSFUSION, AUTOLOGOUS; HOSPITAL MORTALITY; HUMANS; LENGTH OF STAY; PERIOPERATIVE CARE; RISK; TREATMENT OUTCOME;

EID: 33646050665     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aco.0000192798.10420.45     Document Type: Review

References (105)

1. Stanworth SJ, Cockburn HA, Boralessa H, et al. Which groups of patients are transfused? A study of red cell usage in London and southeast England. Vox Sang 2002; 83:352-357.
2. Morisaki H, Sibbald WJ. Tissue oxygen delivery and the microcirculation. Crit Care Clin 2004; 20:213-223.
3. Hébert PC, Van der Linden P, Biro G, et al. Physiologic aspects of anemia. Crit Care Clin 2004; 20:187-212.
4. Karger R, Kretschmer V, Wulf H. Risks of blood transfusion-current incidence data for 'quantitative' patient information [In German]. Anaesthesiol Intensivmed 2004; 45:430-434.
5. Marcucci C, Madjdpour C, Spahn DR. Allogeneic blood transfusions: benefit, risks and clinical indications in countries with a low or high human development index. Br Med Bull 2004; 70:15-28.
6. Kinde G, Oke J, Gnahoui I, et al. The risk of malaria transmission by blood transfusion at Cotonou, Benin. Sante 2000; 10:389-392.
7. Moore A, Herrera G, Nyamongo J, et al. Estimated risk of HIV transmission by blood transfusion in Kenya. Lancet 2001; 358:657-660.
8. Candotti D, Sarkodie F, Allain JP. Residual risk of transfusion in Ghana. Br J Haematol 2001; 113:37-39.
9. Offner PJ. Age of blood: does it make a difference? Crit Care 2004; 8 (Suppl 2):S24-S26.
10. van Bommel J, de Korte D, Lind A, et al. The effect of the transfusion of stored RBCs on intestinal microvascular oxygenation in the rat. Transfusion 2001; 41:1515-1523.
11. Silliman CC, Thurman GW, Ambruso DR. Stored blood components contain agents that prime the neutrophil NADPH oxidase through the platelet-activating-factor receptor. Vox Sang 1992; 63:133-136.
12. Marik PE, Sibbald WJ. Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. JAMA 1993; 269:3024-3029.
13. Vamvakas EC, Carven JH. Transfusion and postoperative pneumonia in coronary artery bypass graft surgery: effect of the length of storage of transfused red cells. Transfusion 1999; 39:701-710.
14. Purdy FR, Tweeddale MG, Merrick PM. Association of mortality with age of blood transfused in septic ICU patients. Can J Anaesth 1997; 44:1256-1261.
15. Walsh TS, McArdle F, McLellan SA, et al. Does the storage time of transfused red blood cells influence regional or global indexes of tissue oxygenation in anemic critically ill patients? Crit Care Med 2004; 32:364-371.
16. Napolitano LM, Corwin HL. Efficacy of blood transfusion in the critically ill: does age of blood make a difference? Crit Care Med 2004; 32:594-595.
17. Napolitano LM, Corwin HL. Efficacy of red blood cell transfusion in the critically ill. Crit Care Clin 2004; 20:255-268.
18. Ho J, Sibbald WJ, Chin-Yee IH. Effects of storage on efficacy of red cell transfusion: when is it not safe? Crit Care Med 2003; 31 (12 Suppl):S687-S697.
19. Opelz G, Sengar DP, Mickey MR, et al. Effect of blood transfusions on subsequent kidney transplants. Transplant Proc 1973; 5:253-259.
20. Gantt CL. Red blood cells for cancer patients. Lancet 1981; 2:363.
21. Vamvakas EC, Blajchman MA. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood 2001; 97:1180-1195.
22. Blumberg N, Heal JM. Effects of transfusion on immune function. Cancer recurrence and infection. Arch Pathol Lab Med 1994; 118:371-379.
23. Duffy G, Neal KR. Differences in post-operative infection rates between patients receiving autologous and allogeneic blood transfusion: a meta-analysis of published randomized and nonrandomized studies. Transfus Med 1996; 6:325-328.
24. Francis DM. Relationship between blood transfusion and tumour behaviour. Br J Surg 1991; 78:1420-1428.
25. Vamvakas EC. Perioperative blood transfusion and cancer recurrence: meta-analysis for explanation. Transfusion 1995; 35:760-768.
26. Vamvakas EC, Moore SB. Blood transfusion and postoperative septic complications. Transfusion 1994; 34:714-727.
27. Busch OR, Hop WC, Hoynck van Papendrecht MA, et al. Blood transfusions and prognosis in colorectal cancer. N Engl J Med 1993; 328:1372-1376.
28. Heiss MM, Mempel W, Delanoff C, et al. Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. J Clin Oncol 1994; 12:1859-1867.
29. Houbiers JG, Brand A, van de Watering LM, et al. Randomised controlled trial comparing transfusion of leucocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer. Lancet 1994; 344:573-578.
30. Heiss MM, Mempel W, Jauch KW, et al. Beneficial effect of autologous blood transfusion on infectious complications after colorectal cancer surgery. Lancet 1993; 342:1328-1333.
31. Jensen LS, Andersen AJ, Christiansen PM, et al. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br J Surg 1992; 79:513-516.
32. Jensen LS, Kissmeyer-Nielsen P, Wolff B, et al. Randomised comparison of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery. Lancet 1996; 348:841-845.
33. Van de Watering LM, Hermans J, Houbiers JG, et al. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial. Circulation 1998; 97:562-568.
34. Tartter PI, Mohandas K, Azar P, et al. Randomized trial comparing packed red cell blood transfusion with and without leukocyte depletion for gastrointestinal surgery. Am J Surg 1998; 176:462-466.
35. Busch OR, Hop WC, Marquet RL, et al. Autologous blood and infections after colorectal surgery. Lancet 1994; 343 (8898):668 (author reply 668-669).
36. Bordin JO, Heddle NM, Blajchman MA. Biologic effects of leukocytes present in transfused cellular blood products. Blood 1994; 84:1703-1721.
37. Ghio M, Contini P, Mazzei C, et al. In vitro immunosuppressive activity of soluble HLA class I and Fas ligand molecules: do they play a role in autologous blood transfusion? Transfusion 2001; 41:988-996.
38. Magee CC, Sayegh MH. Peptide-mediated immunosuppression. Curr Opin Immunol 1997; 9:669-675.
39. Nielsen HJ, Reimert CM, Pedersen AN, et al. Time-dependent, spontaneous release of white cell- and platelet-derived bioactive substances from stored human blood. Transfusion 1996; 36:960-965.
40. FDA. A concept paper on prestorage leukocyte reduction of transfusion blood components. http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3620b2d.pdf.
41. Lane TA, Anderson KC, Goodnough LT, et al. Leukocyte reduction in blood component therapy. Ann Intern Med 1992; 117:151-162.
42. Shapiro MJ. To filter blood or universal leukoreduction: what is the answer? Crit Care 2004; 8 (Suppl 2):S27-S30.
43. Lee TH, Paglieroni T, Utter GH, et al. High-level long-term white blood cell microchimerism after transfusion of leukoreduced blood components to patients resuscitated after severe traumatic injury. Transfusion 2005; 45:1280-1290. Very interesting study showing the long-term existence of donor white blood cells in the recipient even after filtration.
44. Dzik S, Aubuchon J, Jeffries L, et al. Leukocyte reduction of blood components: public policy and new technology. Transfus Med Rev 2000; 14:34-52.
45. Balducci L, Benson K, Lyman GH, et al. Cost-effectiveness of white cell-reduction filters in treatment of adult acute myelogenous leukemia. Transfusion 1993; 33:665-670.
46. Gibis B, Baladi JF. In: Leukoreduction: the techniques used, their effectiveness and costs. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 1998.
47. Vamvakas EC, Blajchman MA. Universal WBC reduction: the case for and against. Transfusion 2001; 41:691-712.
48. Chmell MJ, Schwartz HS. Analysis of variables affecting wound healing after musculoskeletal sarcoma resections. J Surg Oncol 1996; 61:185-189.
49. Blumberg N, Heal JM. Effects of transfusion on immune function. Cancer recurrence and infection. Arch Pathol Lab Med 1994; 118:371-379.
50. Vamvakas EC. Meta-analysis of randomized controlled trials investigating the risk of postoperative infection in association with white blood cell-containing allogeneic blood transfusion: the effects of the type of transfused red blood cell product and surgical setting. Transfus Med Rev 2002; 16:304-314.
51. van Hilten JA, Brand A. A multi-center prospective randomized trial of buffy coat depletedand leukocyte filtered erythrocyte transfusions in vascular-and gastrointestinal oncologic surgery. Vox Sang 2002; 83 (Suppl 1):453-456.
52. Weber EW, Slappendel R, Prins MH, et al. Perioperative blood transfusions and delayed wound healing after hip replacement surgery: effects on duration of hospitalization. Anesth Analg 2005; 100:1416-1421.
53. Fergusson D, Hebert P, Shapiro S. The before/after study design in transfusion medicine: methodologic considerations. Transfus Med Rev 2002; 16:296-303.
54. Baron JF, Gourdin M, Bertrand M, et al. The effect of universal leukodepletion of packed red blood cells on postoperative infections in high-risk patients undergoing abdominal aortic surgery. Anesth Analg 2002; 94:529-537.
55. Hebert PC, Fergusson D, Blajchman MA, et al. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA 2003; 289:1941-1949.
56. Williamson LM, Murphy MF, Llewelyn C, et al. Leucocyte-depleted blood in prevention of post-operative infections following elective orthopaedic and cardiac procedures. Vox Sang 2002; 83 (Suppl 1):457-460.
57. Fergusson D, Hebert PC, Lee SK, et al. Clinical outcomes following institution of universal leukoreduction of blood transfusions for premature infants. JAMA 2003; 289:1950-1956.
58. Vamvakas EC. White-blood-cell-containing allogeneic blood transfusion, postoperative infection and mortality: a meta-analysis of observational 'before-and-after' studies. Vox Sang 2004; 86:111-119.
59. Volkova N, Klapper E, Pepkowitz SH, et al. A case-control study of the impact of WBC reduction on the cost of hospital care for patients undergoing coronary artery bypass graft surgery. Transfusion 2002; 42:1123-1126.
60. Cook TD, Cambell DT. Quasi-experimentation: design and analysis issues for field settings. Boston, MA: Houghton Mifflin; 1979.
61. Innerhofer P, Klingler A, Klimmer C, et al. Risk for postoperative infection after transfusion of white blood cell-filtered allogeneic or autologous blood components in orthopedic patients undergoing primary arthroplasty. Transfusion 2005; 45:103-110. This very recently published observational study detected higher infection rates in patients receiving WBC-reduced blood compared to autologous blood. Interestingly, patients not being transfused had higher infection rates than autologous transfused patients.
62. Wallis JP, Chapman CE, Orr KE, et al. Effect of WBC reduction of transfused RBCs on postoperative infection rates in cardiac surgery. Transfusion 2002; 42:1127-1134.
63. Bilgin YM, van de Watering LM, Eijsman L, et al. Double-blind, randomized controlled trial on the effect of leukocyte-depleted erythrocyte transfusions in cardiac valve surgery. Circulation 2004; 109:2755-2760.
64. Fergusson D, Khanna MP, Tinmouth A, et al. Transfusion of leukoreduced red blood cells may decrease postoperative infections: two meta-analyses of randomized controlled trials. Can J Anaesth 2004; 51:417-424.
65. Chung M, Steinmetz OK, Gordon PH. Perioperative blood transfusion and outcome after resection for colorectal carcinoma. Br J Surg 1993; 80:427-432.
66. Brand A, Houbiers JG. Clinical studies of blood transfusion and cancer. In: Vamvakas EC, Blajchman MA, editors. Immunomodulatory effects of blood transfusion. Bethesda, MD: AABB Press; 1999. pp. 145-190.
67. Ness PM, Walsh PC, Zahurak M, et al. Prostate cancer recurrence in radical surgery patients receiving autologous or homologous blood. Transfusion 1992; 32:31-36.
68. Fransen E, Maessen J, Dentener M, et al. Impact of blood transfusions on inflammatory mediator release in patients undergoing cardiac surgery. Chest 1999; 116:1233-1239.
69. Habib RH, Zacharias A, Engoren M. Determinants of prolonged mechanical ventilation after coronary artery bypass grafting. Ann Thorac Surg 1996; 62:1164-1171.
70. Sauaia A, Moore FA, Moore EE, et al. Early predictors of postinjury multiple organ failure. Arch Surg 1994; 129:39-45.
71. Sauaia A, Moore FA, Moore EE, et al. Multiple organ failure can be predicted as early as 12 hours after injury. J Trauma 1998; 45:291-301 (discussion 301-303).
72. Maetani S, Nishikawa T, Tobe T, et al. Role of blood transfusion in organ system failure following major abdominal surgery. Ann Surg 1986; 203:275-281.
73. Moore FA, Moore EE, Sauaia A. Blood transfusion. An independent risk factor for postinjury multiple organ failure. Arch Surg 1997; 132:620-624 (discussion 624-625).
74. Peerless JR, Alexander JJ, Pinchak AC, et al. Oxygen delivery is an important predictor of outcome in patients with ruptured abdominal aortic aneurysms. Ann Surg 1998; 227:726-732 (discussion 732-734).
75. Corwin HL. Blood transfusion: first, do no harm! Chest 1999; 116:1149-1150.
76. Vamvakas EC, Carven JH. Allogeneic blood transfusion and postoperative duration of mechanical ventilation. Transfusion 2001; 41:885-892.
77. Gu YJ, de Vries AJ, Boonstra PW, et al. Leukocyte depletion results in improved lung function and reduced inflammatory response after cardiac surgery. J Thorac Cardiovasc Surg 1996; 112:494-500.
78. Hachida M, Hanayama N, Okamura T, et al. The role of leukocyte depletion in reducing injury to myocardium and lung during cardiopulmonary bypass. ASAIO J 1995; 41:M291-M294.
79. Olivencia-Yurvati AH, Ferrara CA, Tierney N, et al. Strategic leukocyte depletion reduces pulmonary microvascular pressure and improves pulmonary status post-cardiopulmonary bypass. Perfusion 2003; 18 (Suppl 1):23-31.
80. Karaiskos TE, Palatianos GM, Triantafillou CD, et al. Clinical effectiveness of leukocyte filtration during cardiopulmonary bypass in patients with chronic obstructive pulmonary disease. Ann Thorac Surg 2004; 78:1339-1344.
81. Vamvakas EC, Carven JH. RBC transfusion and postoperative length of stay in the hospital or the intensive care unit among patients undergoing coronary artery bypass graft surgery: the effects of confounding factors. Transfusion 2000; 40:832-839.
82. Dzik WH, Anderson JK, O'Neill EM, et al. A prospective, randomized clinical trial of universal WBC reduction. Transfusion 2002; 42:1114-1122.
83. Vamvakas EC. WBC-containing allogeneic blood transfusion and mortality: a meta-analysis of randomized controlled trials. Transfusion 2003; 43:963-973.
84. Vamvakas EC, Taswell HF. Epidemiology of blood transfusion. Transfusion 1994; 34:464-470.
85. Blajchman MA. Transfusion-associated immunomodulation and universal white cell reduction: are we putting the cart before the horse? Transfusion 1999; 39:665-670.
86. Goodnough LT, Shander A, Spence R. Bloodless medicine: clinical care without allogeneic blood transfusion. Transfusion 2003; 43:668-676.
87. Smoller BR, Kruskall MS. Phlebotomy for diagnostic laboratory tests in adults. Pattern of use and effect on transfusion requirements. N Engl J Med 1986; 314:1233-1235.
88. Strumper D, Weber EW, Gielen-Wijffels S, et al. Clinical efficacy of postoperative autologous transfusion of filtered shed blood in hip and knee arthroplasty. Transfusion 2004; 44:1567-1571.
89. Thomas MJ. Infected and malignant fields are an absolute contraindication to intraoperative cell salvage: fact or fiction? Transfus Med 1999; 9:269-278.
90. Rebarber A, Lonser R, Jackson S, et al. The safety of intraoperative autologous blood collection and autotransfusion during cesarean section. Am J Obstet Gynecol 1998; 179:715-720.
91. Gray CL, Amling CL, Polston GR, et al. Intraoperative cell salvage in radical retropubic prostatectomy. Urology 2001; 58:740-745.
92. Mirhashemi R, Averette HE, Deepika K, et al. The impact of intraoperative autologous blood transfusion during type III radical hysterectomy for early-stage cervical cancer. Am J Obstet Gynecol 1999; 181:1310-1315 (discussion 1315-1316).
93. Waters JH, Biscotti C, Potter PS, et al. Amniotic fluid removal during cell salvage in the cesarean section patient. Anesthesiology 2000; 92:1531-1536.
94. Jones JA. Red blood cell substitutes: current status. Br J Anaesth 1995; 74:697-703.
95. Kasper SM, Grune F, Walter M, et al. The effects of increased doses of bovine hemoglobin on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery. Anesth Analg 1998; 87:284-291.
96. Keipert PE. Use of Oxygent, a perfluorochemical-based oxygen carrier, as an alternative to intraoperative blood transfusion. Artif Cells Blood Substit Immobil Biotechnol 1995; 23:381-394.
97. Ma Z, Monk TG, Goodnough LT, et al. Effect of hemoglobin- and Perflubron-based oxygen carriers on common clinical laboratory tests. Clin Chem 1997; 43:1732-1737.
98. Maguire PJ, Stevens C, Humes HD, et al. Bioartificial organ support for hepatic, renal, and hematologic failure. Crit Care Clin 2000; 16:681-694.
99. O'Hara JF Jr, Colburn WA, Tetzlaff JE, et al. Hemoglobin and methemoglobin concentrations after large-dose infusions of diaspirin cross-linked hemoglobin. Anesth Analg 2001; 92:44-48.
100. Scott MG, Kucik DF, Goodnough LT, et al. Blood substitutes: evolution and future applications. Clin Chem 1997; 43:1724-1731.
101. Sloan EP, Koenigsberg M, Gens D, et al. Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. JAMA 1999; 282:1857-1864.
102. Spahn DR, van Brempt R, Theilmeier G, et al. Perflubron emulsion delays blood transfusions in orthopedic surgery. European Perflubron Emulsion Study Group. Anesthesiology 1999; 91:1195-1208.
103. Stowell CP, Levin J, Spiess BD, et al. Progress in the development of RBC substitutes. Transfusion 2001; 41:287-299.
104. Winslow RM. Blood substitutes - a moving target. Nat Med 1995; 1:1212-1215.
105. Winslow RM. Blood substitutes. Curr Opin Hematol 2002; 9:146-151.